The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Exploring the Complement System in Human Disease

Exploring the Complement System in Human Disease

February 1, 2010 • By M. Kathryn Liszewski and John P. Atkinson, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The complement system has long been the scourge of many a medical student (and even a few rheumatologists), although evidence for its importance in normal as well as aberrant immune function is overwhelming. With its multiple pathways and myriad components, regulators, and receptors, this simple little proteolytic cascade (as described by one medical student when compared to immune signaling pathways and all those “kines”) is a major player in innate immunity and instructs the adaptive immune response. Designed to handle bacterial as well as viral infections, especially to block their invasion into the bloodstream, the complement system is also a key participant in the immune and inflammatory response at sites of tissue injury and debris deposition. It is in these arenas that this key participant in innate immunity may turn out to have its greatest impact in clinical medicine.

You Might Also Like
  • Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease
  • Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease
  • Complement Polymorphism Plays Role in RA Pathology
Explore This Issue
February 2010

Thanks to whole genome screens, mutations and polymorphisms have now been identified in protein sequences of complement inhibitory proteins (CIPs), which are key regulators of this system, and shown to predispose to human disease. What is most striking about these genetic studies is the unexpected nature of the disease associations and the role of CIPs in clinically highly disparate diseases that affect both the young and old.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This review will focus on two important examples of complement system dysfunction: one an acute endothelial injury syndrome and the other a chronic inflammatory reaction to biological debris. For both diseases, new and unequivocal evidence demonstrates that the complement system plays a critical role in pathogenesis. These data were initially obtained from whole genome screens and then extended and confirmed by candidate gene mutational screening. We like to call this approach “the genetic hammer” because arguments about the relevance of the genetics and its role in causality are easy to make in the setting of function-altering mutations. Thus, an emerging theme over the past decade is that surprisingly subtle modulation of complement inhibitory function predisposes to microthromboangiopathies, including the antiphospholipid syndrome.1–4

Five years ago, an even greater surprise was the discovery of the association of age-related macular degeneration (AMD) with a polymorphism in a complement regulator.5–8 The seemingly unrelated pathologies of hemolytic uremic syndrome (HUS) and AMD share the common theme of overactivity of the alternative pathway (AP).1–4,9 The breakthroughs in understanding these diseases came from whole genome screens that identified rare variants leading to haploinsufficiency in HUS and a common polymorphism in which the minor allele has reduced function in AMD. These hypomorphs (i.e., genetically based changes resulting in functionally deficient CIPs that control the AP) are present in at least 50% of patients with certain forms of HUS and account for approximately 50% of the attributable genetic risk for AMD. In neither of these diseases was there much preceding evidence for a role for the complement system, although the presence of activation fragments and inhibitors had been well documented in the retina of AMD patients.9

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Figure 1: The amplification or feedback loop of the alternative pathway.
click for large version
Figure 1: The amplification or feedback loop of the alternative pathway. Activation of C3 is the central step in the complement cascade. C3b is generated and binds to targets where it is amplified. As an example of the potency of the feedback loop, if an E. coli is placed in human serum (even in the absence of any antibodies or lectins that bind to the organism), the alternative pathway feedback loop can deposit several million C3bs on the organism in a few minutes. Microbial death then follows secondary to phagocytosis or lysis.

An Ancient System for Host Defense

First identified in human serum in the late nineteenth century as a “complement” to Ab in causing bacterial lysis, the complement system emerged more than a billion years ago as what was probably the first humoral immune system. Coral, sponges, sea urchins, and horseshoe crabs have an AP essentially identical to the one humans possess.10 For example, the addition of endotoxin to hemolymph of the horseshoe crab leads to activation of a protease that then triggers both the clotting and complement cascades.11 Crabs don’t want “bad bugs” in their circulatory system any more than humans do!

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Conditions, Education & Training, Research Reviews Tagged With: complement system, genetics, genome screens, Immunity, inflammation, Macular degenerationIssue: February 2010

You Might Also Like:
  • Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease
  • Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease
  • Complement Polymorphism Plays Role in RA Pathology
  • The Expanded Role of the Inflammasome in Human Disease

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)